Medison pharma and alnylam pharmaceuticals announce expansion of their multi-regional partnership in europe and israel to commercialize rnai therapeutics in additional latam and apac markets including australia

The expanded partnership will allow alnylam and medison to help accelerate access for patients in multiple regions under one global alliance medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient global commercialization of alnylam's innovative rnai technologies zug, switzerland, april 30, 2024 /prnewswire/ -- medison pharma ("medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, and alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today a further expansion of their existing partnership in central & eastern europe and israel, to also include selected markets in latam and apac and additional international markets. medison, the creator and leader of the multi-regional partnership category, has established a unique, unified commercialization platform in international markets, particularly for the treatment of rare and severe diseases.
ALNY Ratings Summary
ALNY Quant Ranking